Sign In
Buy ARDX
$4.95
-0.0900 (-1.79%)
At Close: Jul 31, 2026
New Strong Sell Stocks for July 29th
06:31am, Wednesday, 29'th Jul 2026
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
08:01am, Thursday, 23'rd Jul 2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commerc
New Strong Sell Stocks for July 23rd
06:46am, Thursday, 23'rd Jul 2026
ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
06:43pm, Tuesday, 23'rd Jun 2026
According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000. The sale represented 17.8% o
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
08:07am, Thursday, 04'th Jun 2026
Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
08:01am, Tuesday, 19'th May 2026
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercia
Ardelyx: Low Price, But High Implied Valuation
10:55am, Friday, 08'th May 2026
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optiona
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings
08:01am, Thursday, 07'th May 2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines tha
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
10:01pm, Thursday, 30'th Apr 2026
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
07:26pm, Thursday, 30'th Apr 2026
Ardelyx (ARDX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
07:01pm, Thursday, 30'th Apr 2026
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare t
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 30'th Apr 2026
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 28'th Apr 2026
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
08:01am, Monday, 27'th Apr 2026
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select
Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know
11:03am, Thursday, 23'rd Apr 2026
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
